The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, ...

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis ...

Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker ...

The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to ...

Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Treatment challenges that Anasuya Gunturi, MD, PhD, encounters in her work at Lowell General Hospital include language ...

“SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, ...

Real-world evidence on infection risks from multiple sclerosis treatments remains limited, with inconsistent findings ...

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with ...